Tobacco & Nicotine Harm Reduction
Advancing Tobacco & Nicotine Harm Reduction Research
CenExel partners with sponsors to evaluate innovative tobacco harm reduction and nicotine delivery solutions through scientifically rigorous clinical research. Our experienced research teams support studies focused on behavioral science, product evaluation, abuse liability, and reduced-risk nicotine alternatives across diverse adult populations.
Studies Conducted
0
+
Trial Participants
0
+
Active Sites
0
+
Overview
Specialized Research for Tobacco & Nicotine Innovation
CenExel provides end-to-end clinical research support for tobacco harm reduction and nicotine-related studies. Our multidisciplinary teams deliver operational excellence, participant recruitment expertise, and high-quality data collection to help sponsors evaluate emerging products and behavioral outcomes with confidence.
Conditions Covered
Tobacco & Nicotine Research Focus Areas
Our research programs support a wide range of tobacco harm reduction and nicotine-related clinical studies.
- Tobacco Harm Reduction
- Nicotine Replacement Therapies
- Electronic Nicotine Delivery Systems (ENDS)
- Smoking Cessation Studies
- Behavioral Dependence Research
- Reduced-Risk Product Evaluation
- Abuse Liability Assessment
- Dual Use Behavior Studies
Our Approach
Why Sponsors Choose CenExel for Tobacco & Nicotine Research
CenExel combines experienced investigators, advanced participant recruitment strategies, and operational excellence to support successful tobacco and nicotine harm reduction clinical trials.
01
Experienced Research Teams
Our investigators support complex tobacco and nicotine studies with high-quality clinical oversight and regulatory expertise.
02
Diverse Participant Access
Access to active smokers, former smokers, dual users, and nicotine-dependent populations across multiple demographics.
03
Behavioral & Product Expertise
Support for behavioral interventions, digital cessation programs, nicotine replacement therapies, and reduced-risk product studies.
04
Rapid Enrollment
Our centralized recruitment and site network accelerate enrollment timelines for tobacco and nicotine trials.
Phase Coverage
Supported Tobacco & Nicotine Trial Phases
CenExel supports early and late-phase tobacco and nicotine harm reduction studies — from first-in-human product evaluations through large-scale post-market research.
Active across all phases
- Phase I
- Phase II
- Phase III
- Phase IV
Tobacco & Nicotine Task Force
CenExel supports innovative tobacco and nicotine-related clinical research through experienced operational teams, rapid recruitment strategies, and high-quality participant engagement across multiple U.S. sites.
Active Sites
18 Sites
CenExel Phoenix
CenExel Anaheim
CenExel Atlanta
CenExel Marlton
CenExel Gaithersburg
